Olorinab (APD371), a peripherally restricted, highly selective, full agonist of the cannabinoid receptor type 2 (CB2), reduces visceral hypersensitivity in animal models

被引：0
|
作者：
Castro, J. [1 ]
Maddern, J. [1 ]
Garcia-Caraballo, S. [1 ]
Lumsden, A. [1 ]
Lindstrom, B. [2 ]
Adams, J. [2 ]
Brierley, S. M. [1 ]
机构：
[1] Flinders Univ S Australia, Visceral Pain Res Grp, SAHMRI, Adelaide, SA, Australia
[2] Arena Pharmaceut Inc, San Diego, CA USA
来源：
NEUROGASTROENTEROLOGY AND MOTILITY | 2019年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
15
引用
收藏
页数：2
相关论文
共 50 条
  • [1] OLORINAB (FORMERLY APD371), A PERIPHERALLY RESTRICTED, HIGHLY SELECTIVE, FULL AGONIST OF THE CANNABINOID RECEPTOR 2 (CB2), REDUCES VISCERAL HYPERSENSITIVITY IN ANIMAL MODELS
    Castro, Joel
    Maddern, Jessica
    Garcia-Caraballo, Sonia
    Lumsden, Amanda L.
    Lindstrom, Beatriz
    Adams, John
    Brierley, Stuart
    GASTROENTEROLOGY, 2019, 156 (06) : S382 - S382
  • [2] APD371, a peripherally restricted, highly selective, full agonist of the Cannabinoid Receptor 2 (CB2), reduces colitis-induced visceral hypersensitivity in rats
    Brierley, S.
    Castro, J.
    Maddern, J.
    Garcia-Caraballo, S.
    Lindstrom, B.
    Adams, J.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2018, 30
  • [3] Olorinab, a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2 (CB2), reduces visceral hypersensitivity in mice
    Castro, Joel
    Maddern, Jessica
    Garcia-Caraballo, Sonia
    Schober, Gudrun
    Lindstrom, Beatriz
    Schmiel, Shirdi
    Brierley, Stuart M.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2020, 32
  • [4] Olorinab (APD371), a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2, reduces colitis-induced acute and chronic visceral hypersensitivity in rodents
    Castro, Joel
    Garcia-Caraballo, Sonia
    Maddern, Jessica
    Schober, Gudrun
    Lumsden, Amanda
    Harrington, Andrea
    Schmiel, Shirdi
    Lindstrom, Beatriz
    Adams, John
    Brierley, Stuart M.
    PAIN, 2022, 163 (01) : E72 - E86
  • [5] PHARMACOKINETICS (PK) AND SAFETY OF OLORINAB (APD371), A HIGHLY SELECTIVE, PERIPHERALLY ACTING FULL AGONIST OF THE CANNABINOID RECEPTOR 2 (CB2), IN HEALTHY ADULT SUBJECTS.
    Stauber, K.
    Oh, D.
    Tang, Y.
    Lindstrom, B.
    English, B.
    Cabell, C.
    Ruckle, J.
    Searle, S.
    Kam, J.
    Jones, R.
    Grundy, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S79 - S79
  • [6] CANNABINOID RECEPTOR EXPRESSION AND THE EFFECT OF OLORINAB, A PERIPHERALLY ACTING, HIGHLY SELECTIVE, FULL AGONIST OF THE CANNABINOID RECEPTOR 2 (CB2), IN RODENTS WITH COLITIS AND CHRONIC VISCERAL HYPERSENSITIVITY
    Castro, Joel
    Maddern, Jessica
    Garcia-Caraballo, Sonia
    Schober, Gudrun
    Lindstrom, Beatriz
    Schmiel, Shirdi
    Brierley, Stuart
    GASTROENTEROLOGY, 2020, 158 (06) : S269 - S269
  • [7] Discovery of APD371: Identification of a Highly Potent and Selective CB2 Agonist for the Treatment of Chronic Pain
    Han, Sangdon
    Thoresen, Lars
    Jung, Jae-Kyu
    Zhu, Xiuwen
    Thatte, Jayant
    Solomon, Michelle
    Gaidarov, Ibragim
    Unett, David J.
    Yoon, Woo Hyun
    Barden, Jeremy
    Sadeque, Abu
    Usmani, Amin
    Chen, Chuan
    Semple, Graeme
    Grottick, Andrew J.
    Al-Shamma, Hussein
    Christopher, Ronald
    Jones, Robert M.
    ACS MEDICINAL CHEMISTRY LETTERS, 2017, 8 (12): : 1309 - 1313
  • [8] OLORINAB, A PERIPHERALLY RESTRICTED, HIGHLY SELECTIVE AGONIST OF THE CANNABINOID RECEPTOR TYPE 2 FOR THE MANAGEMENT OF VISCERAL PAIN IN INFLAMMATORY BOWEL DISEASE (IBD) - PRECLINICAL AND EARLY CLINICAL DEVELOPMENT
    Lindstrom, Beatriz F.
    Ruckle, Jon L.
    Turner, Stewart A.
    Stauber, Kathe
    Brierley, Stuart M.
    English, Brett A.
    Yacyshyn, Bruce
    GASTROENTEROLOGY, 2019, 156 (03) : S92 - S93
  • [9] OLORINAB, A PERIPHERALLY RESTRICTED, HIGHLY SELECTIVE AGONIST OF THE CANNABINOID RECEPTOR TYPE 2 FOR THE MANAGEMENT OF VISCERAL PAIN IN INFLAMMATORY BOWEL DISEASE (IBD) - PRECLINICAL AND EARLY CLINICAL DEVELOPMENT
    Lindstrom, Beatriz F.
    Ruckle, Jon L.
    Turner, Stewart A.
    Stauber, Kathe
    Brierley, Stuart M.
    English, Brett A.
    Yacyshyn, Bruce
    INFLAMMATORY BOWEL DISEASES, 2019, 25 : S64 - S64
  • [10] A combination of peripherally restricted CB1 and CB2 cannabinoid receptor agonists reduces bladder afferent sensitisation in cystitis
    Ramsay, Stewart
    Yew, Wai Ping
    Brookes, Simon
    Zagorodnyuk, Vladimir
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2024, 985
12345